Across TCGA cell cohorts, ZNF630 mutation is significantly associated with the drug of many other genes, with 25 significant associations in total. BREAST shows the largest number of these associations.

The most reproducible ZNF630-associated genes across cancer lineages are BAY-HDAC11_1, Bleomycin (10 uM), and AZD4877. Each is linked with ZNF630 in more than 1 cancer types. Because this analysis shows association rather than direction, both ZNF630-to-partner and partner-to-ZNF630 results are reported.

Each partner links to its own Q-omics profile.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (ZNF630→partner) and Y-score (partner→ZNF630) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BREAST	BAY-HDAC11_1 →	-0.762	-2.807	<.001	.045	3	1
BREAST	Bleomycin (10 uM) →	-0.599	-2.807	.034	.047	3	1
BREAST	AZD4877 →	-0.655	-2.807	.028	.047	3	1
BREAST	MCT4_1422 →	-0.354	-2.807	.032	.047	3	1
BREAST	RAF_9304 →	-0.375	-2.687	.029	.049	3	1
BREAST	Ponatinib →	-0.359	-2.807	.044	.047	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 25 associations by consensus.

Exploration

ZNF630 survival (RNA) · tumor vs normal (RNA) · all ZNF630 data types